Kewaunee Scientific Corporation KEQU
34.02
(0.26)
(0.76%)
as of 25 Sep
- Market cap
- $99.3M
- P/E
- 11.9×
Follow KEQU
Growth Flags
show if company had growth for consecutive years
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
12.49 | 11.05 | 10.39 | 10.20 |
+8 more quarters Free account |
P/S ratio |
0.37 | 0.38 | 0.40 | 0.42 | |
P/FCF ratio |
9.46 | 7.21 | 6.04 | 23.40 | |
P/Operating CF |
52.06 | 19.41 | 9.89 | (28.10) | |
P/B ratio |
1.33 | 1.38 | 1.59 | 1.67 | |
Price to Tangible BV |
2.11 | 2.21 | 2.66 | 2.84 | |
EV/Sales |
0.50 | 0.50 | 0.53 | 0.59 | |
EV/EBITDA |
6.29 | 5.98 | 5.66 | 6.38 | |
EV/Operating CF |
9.30 | 7.56 | 6.77 | 19.39 | |
EV/FCF |
12.66 | 9.59 | 8.02 | 32.82 | |
Quick Ratio |
1.45 | 1.46 | 1.32 | 1.59 | |
Current Ratio |
2.20 | 2.18 | 2.12 | 2.48 | |
Net Debt/EBITDA |
7.26 | 5.13 | 8.38 | 8.34 | |
Debt/Assets |
25.69% | 26.14% | 27.31% | 32.74% | |
Debt/Equity |
0.58 | 0.61 | 0.66 | 0.86 | |
Asset Turnover |
1.50 | 1.51 | 1.58 | 1.76 | |
Operating CF/Net income |
1.16 | 1.61 | 16.83 | (1.74) | |
Capex/Depreciation |
(0.47) | (0.58) | (0.35) | (0.94) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.16 | 0.16 | 0.17 | 0.16 | |
Share Based Compensation of Revenue |
2.86% | 0.70% | 0.78% | 0.80% | |
Graham Net Nets |
0.05 | 0.04 | 0.00 | (0.03) | |
Graham Number |
41.54 | 44.97 | 46.94 | 48.05 | |
Earnings Yield |
8.01% | 9.05% | 9.63% | 9.80% | |
Free Cash Flow Yield |
10.58% | 13.87% | 16.54% | 4.27% | |
Revenue per Share |
23.03 | 24.94 | 24.21 | 24.46 | |
Operating CF per Share |
0.69 | 1.91 | 4.06 | (1.49) | |
Capex per Share |
(0.27) | (0.32) | (0.23) | (0.55) | |
Free Cash Flow per Share |
0.42 | 1.58 | 3.83 | (2.04) | |
Cash per Share |
3.56 | 4.06 | 3.61 | 4.77 | |
Shareholders Equity per Share |
26.81 | 26.83 | 25.31 | 25.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
26.81 | 26.83 | 25.31 | 25.02 | |
Free Cash Flow |
1.20 | 4.53 | 10.98 | (5.83) | |
Working Capital |
56.72 | 57.05 | 54.79 | 67.83 | |
Capital Expenditures |
(0.77) | (0.93) | (0.67) | (1.57) | |
Net Current Asset Value |
5.37 | 3.90 | 0.15 | (3.72) | |
EV/EBIT |
9.15 | 8.43 | 7.65 | 8.55 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 | |
Net Profit Margin |
2.57% | 4.75% | 1.00% | 3.49% | |
Price to Operating Income |
6.83 | 6.34 | 5.76 | 6.09 | |
| Other line items | |||||
Average Receivables |
57.55 | 60.56 | 55.78 | 50.45 | |
Average Payables |
23.94 | 24.74 | 24.09 | 22.06 | |
Average Inventory |
32.35 | 31.69 | 32.23 | 27.08 | |
Average Assets |
184.64 | 186.48 | 182.55 | 161.78 | |
Average Common Equity |
73.04 | 71.53 | 67.32 | 66.19 |
Columns are period end dates